These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 35592355)
1. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Brazel D; Zhang S; Nagasaka M Lung Cancer (Auckl); 2022; 13():33-45. PubMed ID: 35592355 [TBL] [Abstract][Full Text] [Related]
2. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives. Fraser M; Seetharamu N; Diamond M; Lee CS Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971 [TBL] [Abstract][Full Text] [Related]
3. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations. Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963 [TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795 [TBL] [Abstract][Full Text] [Related]
5. Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring Hashiguchi MH; Sato T; Yamamoto H; Watanabe R; Kagyo J; Domoto H; Shiomi T JTO Clin Res Rep; 2022 Feb; 3(2):100271. PubMed ID: 35252894 [TBL] [Abstract][Full Text] [Related]
6. The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. Hsu R; Benjamin DJ; Nagasaka M Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509224 [TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping. Yang M; Vioix H; Sachdev R; Stargardter M; Tosh J; Pfeiffer BM; Paik PK Value Health; 2023 Apr; 26(4):487-497. PubMed ID: 36503033 [TBL] [Abstract][Full Text] [Related]
8. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Wu YL; Smit EF; Bauer TM Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553 [TBL] [Abstract][Full Text] [Related]
9. Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With Ninomaru T; Okada H; Fujishima M; Irie K; Fukushima S; Hata A JTO Clin Res Rep; 2021 Mar; 2(3):100145. PubMed ID: 34590003 [TBL] [Abstract][Full Text] [Related]
11. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report. Tseng LW; Chang JW; Wu CE Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109 [TBL] [Abstract][Full Text] [Related]
12. The Current Landscape for Desai A; Cuellar S J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499 [TBL] [Abstract][Full Text] [Related]
13. Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report. Torrado C; Feng J; Faour E; Leighl NB JTO Clin Res Rep; 2024 Apr; 5(4):100647. PubMed ID: 38550296 [TBL] [Abstract][Full Text] [Related]
14. Effective treatment of Kashizaki F; Okazaki S; Tsuchiya N; Chen H; Koizumi H; Takahashi K AME Case Rep; 2024; 8():42. PubMed ID: 38711889 [TBL] [Abstract][Full Text] [Related]
15. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation. Vanderick A; Colinet B Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868 [TBL] [Abstract][Full Text] [Related]
16. Lung Cancer with Fujino T; Suda K; Mitsudomi T Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201 [No Abstract] [Full Text] [Related]
17. Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics. Guo MZ; Marrone KA; Spira A; Waterhouse DM; Scott SC Onco Targets Ther; 2021; 14():5321-5331. PubMed ID: 34853516 [No Abstract] [Full Text] [Related]
18. Real-world experience with capmatinib in Illini O; Fabikan H; Swalduz A; Vikström A; Krenbek D; Schumacher M; Dudnik E; Studnicka M; Öhman R; Wurm R; Wannesson L; Peled N; Kian W; Bar J; Daher S; Addeo A; Rotem O; Pall G; Zer A; Saad A; Cufer T; Sorotsky HG; Hashemi SMS; Mohorcic K; Stoff R; Rovitsky Y; Keren-Rosenberg S; Winder T; Weinlinger C; Valipour A; Hochmair MJ Ther Adv Med Oncol; 2022; 14():17588359221103206. PubMed ID: 35720834 [TBL] [Abstract][Full Text] [Related]
19. Tepotinib hydrochloride for the treatment of non-small cell lung cancer. Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690 [TBL] [Abstract][Full Text] [Related]
20. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation. Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]